Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.44 USD
+0.03 (7.29%)
Updated Apr 25, 2024 03:12 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PBLA 0.44 +0.03(7.29%)
Will PBLA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PBLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PBLA
Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
PBLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
Other News for PBLA
Panbela Therapeutics announces delay of expected data from pancreatic cancer treatment trial
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Panbela Therapeutics Updates ASPIRE Trial Timeline
Panbela announces interim data analysis for ASPIRE trial pushed to Q1 of 2025
Panbela Announces Poster Presentation at American Association for Cancer Research: